Pharmacogenetics of calcineurin inhibitors in renal transplantation

Transplantation

Volumn 88, Issue SUPPL. 3, 2009, Pages

  Coto, Eliecer ^a   Tavira, Beatriz ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Calcineurin inhibitors; Cytochrome P450; Immunosuppressive drugs; Pharmacogenetics; Pharmacokinetics; Renal transplantation.

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; TACROLIMUS;

CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; GENE EXPRESSION; GENETIC VARIABILITY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

ALTERNATIVE SPLICING; CALCINEURIN; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 70349116090     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181afe9e7     Document Type: Review

References (84)

1. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97.
2. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens 2002; 11: 657.
3. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211.
4. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003; 4: 937.
5. Stoughton RB, Friend SH. How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov 2005; 4: 345.
6. Phillips KA, Van Bebber SL. Measuring the value of pharmacogenom-ics. Nat Rev Drug Discov 2005; 4: 500.
7. Shastry BS. Genetic diversity and new therapeutic concepts. J Hum Genet 2005; 50: 321.
8. Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 2005; 6: 163.
9. Ng FL, Holt DW, MacPhee IA. Pharmacogenetics as a tool for optimis-ing drug therapy in solid-organ transplantation. Expert Opin Pharma-cother 2007; 8: 2045.
10. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: One step closer toward individualized immuno-suppression? Pharmacogenomics 2005; 6: 323.
11. Burckart GJ, Liu XI. Pharmacogenetics in transplant patients: Can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 2006; 28: 23.
12. Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements of tacrolimus. Lancet 1996; 348: 1446.
13. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24.
14. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815.
15. Vadivel N, Garg A, Holt DW, et al. Tacrolimus dose in black renal transplant recipients. Transplantation 2007; 83: 997.
16. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15.
17. de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: Current status and future directions. Transplant Rev (Orlando) 2008; 22: 6.
18. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailabil-ity of cyclosporine. Clin Pharmacol Ther 1997; 62: 248.
19. Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62: 25.
20. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25: 231.
21. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374.
22. Kruger B, Schroppel B, Murphy BT. Genetic polymorphisms and the fate of the transplanted organ. Transplant Rev (Orlando) 2008; 22: 131.
23. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807.
24. Rusnak F, Mertz P. Calcineurin: Form and function. Physiol Rev 2000; 80: 1483.
25. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine micro-emulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744.
26. Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 2000; 32: 1689.
27. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159.
28. Iwasaki K, Shiraga T, Nagase K, et al. Pharmacokinetic study of FK 506 in the rat. Transplant Proc 1991; 23: 2757.
29. Vincent SH, Karanam BV, Painter SK, et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992; 294: 454.
30. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22: 328.
31. Yano I. Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors. Drug Metab Pharmacokinet 2008; 23: 150.
32. Iwasaki K, Matsuda H, Nagase K, et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993; 82: 209.
33. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmaco-kinet 2002; 41: 813.
34. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2: 374.
35. Halloran PF, Helms LM, Kung L, et al. The temporal profile of cal-cineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356.
36. Sindhi R, LaVia MF, Paulling E, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine-rapamycin regimen. Transplantation 2000; 69: 432.
37. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024.
38. International Neoral Renal Transplantation Study Group. Cyclospor-ine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
39. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: An international consensus statement. Transplantation 2002; 73(9 suppl): S12.
40. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: A systematic review. Transplantation 2007; 83: 1525.
41. Balbontin FG, Kiberd B, Squires J, et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc 2003; 35: 2445.
42. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 2440.
43. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral)1 in organ transplantation. Drugs 2001; 61: 1957.
44. McLeod HL, Evans WE. Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41: 101.
45. Evans WE, McLeod HL. Pharmacogenomics-Drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538.
46. Cholerton S, Daly AK, Idle JR. The role of individual human cyto-chromes P450 in drug metabolism and clinical response. Trends Phar-macol Sci 1992; 13: 434.
47. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414.
48. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225; erratum in: J Natl Cancer Inst 1999; 91: 1082.
49. Westlind A, Löfberg L, Tindberg N, et al. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5--upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201.
50. Makeeva O, Stepanov V, Puzyrev V, et al. Global pharmacogenetics: Genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics 2008; 9: 847.
51. Quaranta S, Chevalier D, Allorge D, et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica 2006; 36: 1191.
52. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
53. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773.
54. Min DIP, Ellingrod VLP, Marsh SP, et al. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects 1. Ther Drug Monit 2004; 26: 524.
55. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
56. Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharma-cokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
57. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422.
58. Hesselink DA, van Gelder T, van Schaik RHN, et al. Population pharma-cokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545.
59. Kreutz R, Zurcher H, Kain S, et al. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004; 14: 665.
60. Zhao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration the cyclosporine and tacrolimus. Transplant Proc 2005; 37: 178.
61. Gervasini G, Vizcaino S, Gasiba C, et al. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther Drug Monit 2005; 27: 819.
62. Min DI, Ellingrod VL. Association of the CYP3A4*1B 5 flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003; 25: 305.
63. Rivory LP, Qin H, Clarke SJ, et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 2000; 56: 395.
64. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048.
65. Foote CJ, Greer W, Kiberd B, et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007; 83: 1380.
66. Kuzuya T, Kobayashi T, Moriyama N, et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 2003; 76: 865.
67. Mai I, Stormer E, Goldammer M, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003; 43: 1101.
68. Wang P, Heitman J. The cyclophilins. Genome Biol 2005; 6: 226.
69. Moscoso-Solorzano GT, Ortega F, Rodríguez I, et al. A search for cy-clophilin-A gene variants in cyclosporine A-treated renal transplanted patients. Clin Transplant 2008; 22: 722.
70. Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of three polymorphisms with acute rejection after kidney transplantation: Anexploratory pharmacogenetic analysis of a randomized multi-center clinical trial (The Caesar Study). Transplantation 2006; 82: 410.
71. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-todose ratio in renal transplant recipients. Transplantation 2003; 76: 1233.
72. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182.
73. Tada H, Tsuchiya N, Satoh S, et al. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacroli-mus in renal transplant recipients. Transplant Proc 2005; 37: 1730.
74. MacPhee IAM, Fredericks S, Mohamed M, et al. Tacrolimus pharma-cogenetics: The CYP3A5*1 allele predicts low dose-normalized tacroli-mus blood concentrations in whites and South Asians. Transplantation 2005; 79: 499.
75. Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005; 19: 638.
76. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant 2006; 6: 2706.
77. Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659.
78. Mourad M, Wallemacq P, De Meyer M, et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose-and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med 2006; 44: 1192.
79. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term ta-crolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711.
80. MacPhee IAM, Fredericks S, Tai T, et al. Tacrolimus pharmacogenet-ics: Polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486.
81. MacPhee IAM, Fredericks S, Tai T, et al. The influence of pharmaco-genetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914.
82. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889.
83. Akbas SH, Bilgen T, Keser I, et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 2006; 38: 1290.
84. Li D, Gui R, Li J, et al. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. Transplant Proc 2006; 38: 2850.